100
Participants
Start Date
September 2, 2025
Primary Completion Date
July 7, 2027
Study Completion Date
July 7, 2029
Fluorouracil injection
Experimental arm Fluorouracil injection with possible escalation to 75 or 100 percent if tolerated.
Xeloda
Experimental arm Fluorouracil injection with possible escalation to 75 or 100 percent if tolerated.
RWJBarnabas Health Clara Maas Medical Center, Belleville
Trinitas Hospital and Comprehensive Cancer Center, Elizabeth
RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton, Hamilton
RWJBarnabas Health Jersey City Medical Center, Jersey City
Cooperman Barnabas Medical Center, Livingston
Jack and Sheryl Morris Cancer Center, New Brunswick
RWJBarnabas Health - Robert Wood Johnson University Hospita, New Brunswick
Cancer Center Initiative, Newark
University Hospital, Newark
RWJBarnabas Health Newark Beth Israel Medical Center, Newark
RWJBarnabas Health - Robert Wood Johnson University Hospital Somerset, Somerset
RWJBarnabas Health - Community Medical Center, Toms River
Rutgers, The State University of New Jersey
OTHER